Welcome to our dedicated page for Anebulo Pharmaceuticals SEC filings (Ticker: ANEB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anebulo Pharmaceuticals, Inc. (ANEB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Anebulo is a clinical-stage pharmaceutical company developing selonabant (ANEB-001), a CB1 receptor antagonist drug candidate for acute cannabis-induced toxicity in adults and children, and its filings offer detailed insight into this development program and related corporate actions.
For ANEB, current and periodic reports such as Forms 10-K and 10-Q (when available) typically discuss research and development activities, clinical trial status for oral and intravenous selonabant, grant funding from the National Institute on Drug Abuse (NIDA), and risk factors associated with advancing a single lead product candidate. These filings also describe the company’s patent estate around selonabant and summarize its collaboration with regulators, including the U.S. Food and Drug Administration.
Form 8-K filings are particularly important for tracking material events. Recent 8-Ks describe financial results, business updates, and the company’s strategic review and going private plans. One 8-K outlines a proposed reverse stock split structure intended to reduce the number of record holders and enable deregistration and delisting, while a later 8-K reports that the Board abandoned the reverse stock split and chose instead to commence a voluntary self-tender offer to repurchase a specified number of shares at a fixed cash price per share as part of the going private strategy.
On this page, Stock Titan surfaces ANEB filings as they are posted to EDGAR and pairs them with AI-powered summaries that highlight key points, such as changes in clinical trial plans, grant awards, financing arrangements, and corporate transactions. Users can quickly scan the AI summaries for context, then open the full SEC documents for complete details on Anebulo’s operations, financial condition, and material events.
Anebulo Pharmaceuticals, Inc. has filed a Form 25 to remove its common stock from listing and registration on The Nasdaq Stock Market LLC. This step means the company’s common shares will cease to be traded on Nasdaq once the delisting process is completed under the Securities Exchange Act of 1934.
The company states that it has reasonable grounds to believe it meets all requirements to file this notice, and the document is signed by its Chief Executive Officer and Interim Chief Financial Officer. Investors will likely need to trade the shares on alternative markets after the Nasdaq listing is withdrawn.
Nantahala Capital Management, LLC and its principals Wilmot B. Harkey and Daniel Mack report beneficial ownership of 3,547,398 shares of Anebulo Pharmaceuticals common stock, equal to 8.53% of the outstanding shares as of
The filing states these shares are held through funds and separately managed accounts Nantahala controls and include 511,073 shares issuable upon warrant exercise within sixty days. The reporting persons certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Anebulo.
Anebulo Pharmaceuticals, Inc. reported a net loss of $1.999 million for the quarter and $4.158 million for the six months ended December 31, 2025, improving from prior-year losses. Operating expenses fell slightly to $2.620 million for the quarter, as lower R&D was partly offset by higher going‑private related G&A costs.
Cash and cash equivalents were $9.0 million, with total assets of $9.4 million and stockholders’ equity of $7.9 million at December 31, 2025. Management believes cash plus a $3.0 million loan facility will fund operations for at least 12 months. The company continues to advance selonabant, including an ongoing single ascending dose IV study supported by an up to $1.9 million NIH/NIDA grant.
Anebulo is executing a going‑private strategy. It completed a tender offer repurchasing 300,000 shares at $3.50 per share, about 0.73% of shares outstanding as of January 26, 2026, and has announced plans to voluntarily delist from Nasdaq and deregister its common stock, which will end SEC periodic reporting.
Anebulo Pharmaceuticals plans to voluntarily delist its common stock from Nasdaq and deregister with the SEC, ending its regular public reporting. The company expects to file Form 25 around February 17, 2026, with delisting effective February 27, 2026, followed by a Form 15 to suspend reporting obligations, based on having fewer than 300 holders of record. The board cites the high costs and management burden of being a listed reporting company. After delisting, trading would occur only through privately negotiated transactions and potentially over-the-counter markets.
For the quarter ended December 31, 2025, total operating expenses were $2.6 million, flat year over year. Net loss was $2.0 million, or $(0.05) per share, versus a $2.5 million loss, or $(0.09) per share, a year earlier. Cash and cash equivalents were $9.0 million, and the company has access to an additional $3.0 million via a loan agreement.
Anebulo Pharmaceuticals, Inc. announced that its board has approved the voluntary delisting of its common stock from The Nasdaq Capital Market and the voluntary deregistration of its common stock with the SEC to end its Exchange Act reporting obligations.
The company notified Nasdaq of its plan and intends to file a Form 25 on or about February 17, 2026, with the delisting expected to be effective on February 27, 2026. Anebulo also plans to file a Form 15 on or about February 27, 2026, which will immediately suspend its duty to file periodic SEC reports. The board cited the significant costs and management burden of remaining a Nasdaq-listed, SEC-reporting company as the reason for this decision, and noted that any future trading in the stock would likely occur in privately negotiated transactions or potentially on the over-the-counter market.
Anebulo Pharmaceuticals, Inc. filed a final amendment reporting the results of its issuer tender offer to repurchase for cash up to 300,000 shares of its common stock at $3.50 per share. The offer expired at one minute after 11:59 p.m. New York City time on January 26, 2026.
On January 29, 2026, Anebulo issued a press release announcing the final results, which is incorporated by reference as an exhibit. The amendment also lists the related offer documents, fairness opinion materials, and key company agreements that were previously filed and referenced in connection with the transaction.
Anebulo Pharmaceuticals completed its previously announced share tender offer, repurchasing 300,000 shares of common stock at $3.50 per share for an aggregate cost of approximately $1.05 million, excluding fees and expenses.
The offer was oversubscribed, with 4,907,881 shares properly tendered and not withdrawn. After applying a final proration factor of 3.47392%, Anebulo accepted 300,000 shares, including 134,306 odd-lot shares accepted in full. The repurchased shares represent about 0.73% of shares outstanding as of January 26, 2026, with cash payment to sellers to be made promptly.
Anebulo Pharmaceuticals filed Amendment No. 2 to its Schedule TO for an issuer tender offer. The company is offering to purchase for cash up to 300,000 shares of its common stock at $3.50 per share, on the terms described in its Offer to Purchase and related Letter of Transmittal. This amendment updates the filing to include the preliminary results of the tender offer and adds a press release issued on January 27, 2026, describing those preliminary results. The tender offer expired one minute after 11:59 p.m., New York City time, on January 26, 2026, and the press release is incorporated as an exhibit to the filing.
Anebulo Pharmaceuticals reported preliminary results of its cash tender offer to repurchase up to 300,000 shares of its common stock at $3.50 per share. The offer expired on January 26, 2026.
Based on the depositary’s initial count, about 4,897,188 shares were properly tendered and not withdrawn, meaning the offer was oversubscribed. The company currently expects to buy the full 300,000 shares for an estimated total cost of about $1.05 million, excluding related fees and expenses.
Because far more shares were tendered than the company offered to purchase, Anebulo expects to accept shares on a pro rata basis, except that “odd lot” holders will be accepted in full. The preliminary proration factor is approximately 3.51542%, and the shares expected to be purchased represent roughly 0.73% of shares outstanding as of January 26, 2026. Final results will be announced after the guaranteed delivery period and confirmation by the depositary.